We aimed to determine serum soluble Fas antigen (sFas) levels at various stages of hepatitis C virus (HCV)-induced liver disease, and investigate correlations between serum sFas levels and clinical, biochemical and pathologic features. Sixty-five patients were categorized into five groups: 1, chronic active hepatitis C, elevated alanine aminotransferase (ALT), HCV-polymerase chain reaction (PCR) positive;2, responders to interferon + ribavirin therapy; 3, cirrhosis; 4, chronic hepatitis C, normal ALT, HVC-PCR positive;and 5, sustained responders. Group 6 comprised 15 control individuals. Serum sFas levels were measured by enzyme-linked immunosorbent assay. Significant differences in serum sFas levels were found between the following groups: 1 and 2; 1 and 3; 1 and 4; 1 and 6; and 3 and 6. Serum sFas levels did not correlate with ALT, histological activity or HCV-PCR positivity within group 1. Serum sFas levels appear to increase in advanced stages of HCV-induced liver disease, as a result of host-related immunological factors.
AlterMJMastEE: The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am1994; 23: 437–455.
2.
SeeffLBBuskell-BalesZWrightECDurakoSJAlterHJIberFL: Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, Blood Institute Study Group. N Engl J Med1992; 327: 1906–1911.
3.
ChiaramonteMStroffoliniTVianAStaziMAFloreaniALorenzoniU: Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis. Cancer1999; 85: 2132–2137.
4.
ThompsonCB: Apoptosis in the pathogenesis and treatment of disease. Science1995; 267: 1456–1462.
5.
RobertsJSearleJCooksleyW: Histological patterns of prolonged hepatitis C infection. Gastroenterol Jpn1993; 28: 37–41.
6.
KagiDVignauxFLedermannBBurkiKDepraetereVNagataS: Fas and perforin pathways as major mechanisms of T cell-mediated cytotoxicity. Science1994; 265: 528–530.
7.
KozielMJDudleyDWongJTDienstagJHoughtonMRalstonRet al: Intrahepatic cytotoxic T lymphocytes specific for hepatitis C virus in persons with chronic hepatitis. J Immunol1992; 149: 3339–3344.
8.
NagataSGolsteinP: The Fas death factor. Science1995; 267: 1449–1456.
9.
OgasawaraJWatanabe-FukunagaRAdachiMMatsuzawaAKasugaiTKitamuraY: Lethal effects of the anti-Fas antibody in mice. Nature1993; 364: 806–809.
10.
AdachiMWatanabe-FukunagaRNagataS: Aberrant transcription caused by the insertion of an early transposable element in the intron of the Fas antigen gene of lpr mice. Proc Natl Acad Sci U S A1993; 90: 1756–1760.
11.
HiramatsuNHayashiNKatayamaKMochizukiKKawanishiYKasaharaA: Immunohistochemical detection of Fas antigen in liver tissues of patients with chronic hepatitis C. Hepatology1994; 19: 1354–1359.
12.
MitaEHayashiNIioSTakeharaTHijiokaTKasaharaA: Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun1994; 204: 468–474.
13.
CascinoIFiucciGPapoffGRubertiG: Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol1995; 154: 2706–2713.
14.
ChengJZhouTLiuCShapiroJPBrauerMJKieferMC: Protection from Fas-mediated apoptosis by soluble form of the Fas molecule. Science1994; 263: 1759–1762.
15.
JodoSKobayashiSKayagakiNOguraNFengYAmasakiY: Serum levels of soluble Fas/APO1 (CD95) and its molecular structure in patients with systemic lupus erythematosus (SLE) and other autoimmune diseases. Clin Exp Immunol1997; 107: 89–95.
16.
KnippingEDebatinKMStrickerKHeiligBEderAKrammerPH: Identification of soluble APO-1 in supernatants of human B- and T-cell lines and increased serum levels in B- and T-cell leukemias. Blood1995; 85: 1562–1569.
17.
MidisGPShenYOwen-SchaubLB: Elevated soluble Fas (sFas) levels in non-hematopoietic human malignancy. Cancer Res1996; 56: 3870–3874.
18.
IioSHayashiNMitaEUedaKMochizukiKHoramatsuN: Serum levels of soluble Fas antigen in chronic hepatitis C patients. J Hepatol1998; 29: 517–523.
19.
OhkawaKHiramatsuNMochizukiKMitaEIioSYoshiharaH: Significance of serum soluble Fas antigen level in chronic hepatitis C patients treated with interferon: relationship to the therapeutic response. J Gastroenterol Hepatol2001; 16: 1009–1014.
20.
GallePR: Apoptosis in liver disease. J Hepatol1997; 27: 405–412.
21.
SuzukiKEndoRNakamuraNYatomiTIwaiMAbeK: Serum levels of soluble Fas ligand in patients with acute and fulminant hepatitis: relationship with soluble Fas, tumor necrosis factor alpha and TNF receptor-1. Hepatol Res2000; 17: 19–30.
22.
MaciasJSanchez-QuijanoAPinedaJAAbadMARubioARosaR: Minimal liver injury in chronic hepatitis C virus infection is associated with low levels of soluble TNF-alpha/Fas receptors and acquisition in childhood. Liver2001; 21: 410–414.
23.
JodoSKobayashiSNakajimaYMitsunagaTNakayamaNOguraN: Elevated serum levels of soluble Fas/APO-1 (CD95) in patients with hepatocellular carcinoma. Clin Exp Immunol1998; 112: 166–171.
24.
DesmetVJGerberMHoofnagelJHMannsMScheuerPJ: Classification of chronic hepatitis: diagnosis, grading, and staging. Hepatology1994; 19: 1513–1520.
ToyodaMKakizakiSHoriguchiNSatoKTakayamaHTakagiH: Role of serum soluble Fas/soluble Fas ligand and TNF-alpha on response to interferon-alpha therapy in chronic hepatitis C. Liver2000; 20: 305–311.
27.
CalabreseFPontissoPPettenazzoEBenvegnuLVarioAChemelloL: Liver cell apoptosis in chronic hepatitis C correlates with histological but not biochemical activity or serum HCV-RNA levels. Hepatology2000; 31: 1153–1159.
28.
PiankoSPatellaSOstapowiczGDesmondPSievertW: Fas-mediated hepatocyte apoptosis is increased by hepatitis C virus infection and alcohol consumption, and may be associated with hepatic fibrosis: mechanisms of liver cell injury in chronic hepatitis C virus infection. J Viral Hepat2001; 8: 406–413.
29.
YoneyamaKGotoTMiuraKMikamiKOhshimaSNakaneK: The expression of Fas and Fas ligand, and the effects of interferon in chronic liver diseases with hepatitis C virus. Hepatol Res2002; 24: 327–337.
30.
SeishimaMTakemuraMSaitoKAndoKNomaA: Increased serum soluble Fas (sFas) concentrations in HCV-positive patients with liver cirrhosis. J Hepatol1997; 27: 424–427.
31.
OkazakiMHinoKFujiiKKobayashiNOkitaK: Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C. Dig Dis Sci1996; 41: 2453–2458.
